ILAP Designation accelerates patient access and commercializationMIAMI, April 05, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”),...
Glen Rock, N.J., April 05, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a...
Significant reduction of toxic protein aggregate, Poly(GP) Significant increase in biomarker of target engagement, sGPNMB AIT-101 and active metabolites crossed...
AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease Webinar to take place...
-- Children aged 5 to 17 with autism are now eligible to enroll in the clinical trial of AB-2004, a...
MELBOURNE, Australia and SAN FRANCISCO, April 04, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the...
Glen Rock, N.J., April 03, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a...
ROCHESTER, N.Y., April 03, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company...
Expect to complete patient enrollment in the randomized Phase 1/2a SIGNAL-AD Alzheimer’s study in April 2023 with topline data anticipated...
Revenue increased 14% annually driven by greater adoption of medical treatments. BRENTWOOD, Tenn., March 31, 2023 (GLOBE NEWSWIRE) -- IMAC...
$17.5 Million in Cash and Marketable Securities as of December 31, 2022; Expected to Support Operations Into Second Half of...
Company Announcement, Helsinki, 31 March 2023 at 1 PM (EEST) Nexstim Plc: Resolutions of the Annual General Meeting of Shareholders...
TOKYO and CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and...
TOKYO and CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and...
MINNEAPOLIS, March 30, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic...
VANCOUVER, British Columbia, March 30, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “Company”) (TSXV:RKV) today announced the engagement of...
SEATTLE, Wash. and VANCOUVER, British Columbia, March 30, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage...
– Dosed the first patient in VIRAGE, a Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy...
Expects to announce clinical trial data from multiple oncology programs in the second half of 2023Extends cash runway into second...
Apollomics’ Class A ordinary shares and public warrants are expected to begin trading today on the Nasdaq Capital Market under the...